LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Ustekinumab for the treatment of psoriasis: an evidence update.

    Yiu, Zenas Zn / Warren, Richard B

    Seminars in cutaneous medicine and surgery

    2018  Volume 37, Issue 3, Page(s) 143–147

    Abstract: Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head ... ...

    Abstract Ustekinumab is an interleukin-12/23 inhibitor used for the treatment of moderate-to-severe psoriasis. Here, we review new evidence since ustekinumab was licensed for relative efficacy in comparison with other biologic therapies from head-to-head randomized controlled trials and network meta-analyses for the treatment of psoriasis. We also review observational data emerging from psoriasis registries reporting the effectiveness and safety of ustekinumab. Overall, new evidence suggests that ustekinumab has a favorable balance between efficacy/effectiveness, safety, and tolerability and should remain a first-line biologic therapy option for patients with severe psoriasis at present.
    MeSH term(s) Dermatologic Agents/adverse effects ; Dermatologic Agents/therapeutic use ; Humans ; Infections/chemically induced ; Observational Studies as Topic ; Psoriasis/drug therapy ; Psoriasis/genetics ; Randomized Controlled Trials as Topic ; Ustekinumab/adverse effects ; Ustekinumab/therapeutic use
    Chemical Substances Dermatologic Agents ; Ustekinumab (FU77B4U5Z0)
    Language English
    Publishing date 2018-09-14
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1355511-x
    ISSN 1558-0768 ; 1085-5629
    ISSN (online) 1558-0768
    ISSN 1085-5629
    DOI 10.12788/j.sder.2018.040
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1754: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Guselkumab for psoriasis: a critical appraisal of Phase III studies.

    Yiu, Zenas Zn / Warren, Richard B

    Immunotherapy

    2017  Volume 10, Issue 1, Page(s) 67–75

    Abstract: Biologic therapies have raised the frontiers of accepted treatment efficacy for severe psoriasis. Guselkumab is an IgG1 monoclonal antibody that binds to the p19 subunit and inhibits IL-23. In three Phase III randomized, active comparator and placebo ... ...

    Abstract Biologic therapies have raised the frontiers of accepted treatment efficacy for severe psoriasis. Guselkumab is an IgG1 monoclonal antibody that binds to the p19 subunit and inhibits IL-23. In three Phase III randomized, active comparator and placebo controlled trials, guselkumab demonstrated superior efficacy and a comparable safety profile when assessed against adalimumab and ustekinumab. Critical appraisal highlighted uncertainties over risk of bias from missing details in the trial publications that would be overcome with the provision of accompanying trial protocols, as well as the need for a head-to-head trial against an IL-17 inhibitor. Overall, guselkumab is a promising addition to the biologic options for psoriasis due to its high efficacy, safe profile, low immunogenicity and efficacy in ustekinumab and adalimumab nonresponders.
    MeSH term(s) Adalimumab/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Bias ; Clinical Trials, Phase III as Topic ; Humans ; Interleukin-17/antagonists & inhibitors ; Interleukin-17/immunology ; Interleukin-23/antagonists & inhibitors ; Interleukin-23/immunology ; Psoriasis/drug therapy ; Treatment Outcome ; Ustekinumab/therapeutic use
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Interleukin-17 ; Interleukin-23 ; guselkumab (089658A12D) ; Ustekinumab (FU77B4U5Z0) ; Adalimumab (FYS6T7F842)
    Language English
    Publishing date 2017-10-18
    Publishing country England
    Document type Journal Article
    ZDB-ID 2495964-9
    ISSN 1750-7448 ; 1750-743X
    ISSN (online) 1750-7448
    ISSN 1750-743X
    DOI 10.2217/imt-2017-0106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.

    Hanley, Tessa L / Yiu, Zenas Zn

    Therapeutics and clinical risk management

    2017  Volume 13, Page(s) 315–323

    Abstract: Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine ... ...

    Abstract Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine or associated receptors. Ixekizumab is a subcutaneously administered humanized monoclonal antibody, which acts to neutralize IL-17A. This article reviews the role of IL-17 in the pathogenesis of psoriasis, the biological and pharmacokinetics of ixekizumab and the safety profile and the clinical efficacy of ixekizumab in Phase III clinical trials. Phase III clinical trials of ixekizumab have so far demonstrated excellent early clinical efficacy, with a comparable safety profile to the existing biologic therapies for psoriasis. To further assess its position in the treatment algorithm for psoriasis, a further head to head RCT with secukinumab could be established, alongside comparative effectiveness studies from observational research. In addition, trials are needed to assess its role in those with tumor necrosis factor inhibitors/ustekinumab resistant disease. However, it is clear that the IL-17 antagonists have changed the benchmark for clinical efficacy, and it is likely that ixekizumab along with the other IL-17 antagonists are set to achieve a new standard of care in the treatment of moderate to severe plaque psoriasis.
    Language English
    Publishing date 2017-03-13
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2186560-7
    ISSN 1178-203X ; 1176-6336
    ISSN (online) 1178-203X
    ISSN 1176-6336
    DOI 10.2147/TCRM.S111107
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6067: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Assessment and monitoring of biologic drug adverse events in patients with psoriasis.

    Hanley, Tessa / Handford, Marc / Lavery, Dawn / Yiu, Zenas Zn

    Psoriasis (Auckland, N.Z.)

    2016  Volume 6, Page(s) 41–54

    Abstract: Background: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.: Objective: The aim of this paper was to draw together evidence from the currently available guidelines ... ...

    Abstract Background: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.
    Objective: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events.
    Methods: The MEDLINE database was searched to identity the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab.
    Limitations: This study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy.
    Results: This review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility.
    Conclusion: Most screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies.
    Language English
    Publishing date 2016-04-01
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2695573-8
    ISSN 2230-326X
    ISSN 2230-326X
    DOI 10.2147/PTT.S68869
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Factors associated with adverse COVID-19 outcomes in patients with psoriasis - insights from a global registry-based study

    Mahil, Satveer K / Dand, Nick / Mason, Kayleigh J / Yiu, Zenas Zn / Tsakok, Teresa / Meynell, Freya / Coker, Bola / McAteer, Helen / Moorhead, Lucy / Mackenzie, Teena / Rossi, Maria Teresa / Rivera, Raquel / Mahe, Emmanuel / Carugno, Andrea / Magnano, Michela / Rech, Giulia / Balogh, Esther A / Feldman, Steven R / De La Cruz, Claudia /
    Choon, Siew Eng / Naldi, Luigi / Lambert, Jo / Spuls, Phyllis / Jullien, Denis / Bachelez, Hervé / McMahon, Devon E / Freeman, Esther E / Gisondi, Paolo / Puig, Luis / Warren, Richard B / Di Meglio, Paola / Langan, Sinéad M / Capon, Francesca / Griffiths, Christopher Em / Barker, Jonathan N / Smith, Catherine H

    J. allergy clin. immunol

    Abstract: BACKGROUND: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. OBJECTIVE: Characterize the course of COVID-19 in psoriasis and identify ... ...

    Abstract BACKGROUND: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. OBJECTIVE: Characterize the course of COVID-19 in psoriasis and identify factors associated with hospitalization. METHODS: Clinicians reported psoriasis patients with confirmed/suspected COVID-19 via an international registry, PsoProtect. Multiple logistic regression assessed the association between clinical/demographic characteristics and hospitalization. A separate patient-facing registry characterized risk-mitigating behaviours. RESULTS: Of 374 clinician-reported patients from 25 countries, 71% were receiving a biologic, 18% a non-biologic and 10% no systemic treatment for psoriasis. 348 (93%) fully recovered from COVID-19, 77 (21%) were hospitalized and nine (2%) died. Increased hospitalization risk was associated with older age (multivariable-adjusted OR 1.59 per 10 years, 95% CI 1.19-2.13), male sex (OR 2.51, 95% CI 1.23-5.12), non-white ethnicity (OR 3.15, 95% CI 1.24-8.03) and comorbid chronic lung disease (OR 3.87, 95% CI 1.52-9.83). Hospitalization was more frequent in patients using non-biologic systemic therapy than biologics (OR 2.84, 95% CI 1.31-6.18). No significant differences were found between biologic classes. Independent patient-reported data (n=1,626 across 48 countries) suggested lower levels of social isolation in individuals receiving non-biologic systemic therapy compared to biologics (OR 0.68, 95% CI 0.50-0.94). CONCLUSION: In this international moderate-severe psoriasis case series, biologics use was associated with lower risk of COVID-19-related hospitalization than non-biologic systemic therapies, however further investigation is warranted due to potential selection bias and unmeasured confounding. Established risk factors (being older, male, non-white ethnicity, comorbidities) were associated with higher hospitalization rates. CLINICAL IMPLICATIONS: We identify risk factors for COVID-19-related hospitalization in psoriasis patients, including older age, male sex, non-white ethnicity and comorbidities. Use of biologics was associated with lower hospitalization risk than non-biologic systemic therapies.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #866801
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

    Mahil, Satveer K / Yates, Mark / Langan, Sinead M / Yiu, Zenas ZN / Tsakok, Teresa / Dand, Nick / Mason, Kayleigh J / McAteer, Helen / Meynall, Freya / Coker, Bolaji / Vincent, Alexandra / Urmston, Dominic / Vesty, Amber / Kelly, Jade / Lancelot, Camille / Moorhead, Lucy / Bachelez, Herve / Bruce, Ian N / Capon, Francesca /
    Contreras, Claudia Romina / Cope, Andrew P / De La Cruz, Claudia / Di Meglio, Paola / Gisondi, Paolo / Hyrich, Kimme / Jullien, Denis / Lambert, Jo / Waweru, Hoseah / Marzo-Ortega, Helena / McInnes, Iain / Naldi, Luigi / Norton, Sam / Puig, Lluis / Spuls, Phyllis / Sengupta, Raj / Torres, Tiago / Warren, RIchard B / Weinman, John / Griffiths, Christopher EM / Barker, Jonathan N / Brown, Matthew A / Galloway, James B / Smith, Catherine H

    medRxiv

    Abstract: Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international ... ...

    Abstract Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. Methods Online surveys were completed by individuals with Rheumatic and Musculoskeletal Diseases (RMD) (UK only) or psoriasis (globally) between 4th May and 7th September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterised international variation in a mixed effects model. Results Of 3,720 participants (2,869 psoriasis, 851 RMD) from 74 countries, 2,262 (60.8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term shielding). A greater proportion of those receiving targeted therapies (biologics and JAK inhibitors) reported shielding compared to those receiving no systemic therapy (adjusted odds ratio [OR] 1.63, 95% CI 1.35-1.97) and standard systemic agents (OR 1.39, 95% CI 1.22-1.56). Shielding was associated with established risk factors for severe COVID-19 (male sex [OR 1.14, 95% CI 1.05-1.24], obesity [OR 1.38, 95% CI 1.23-1.54], comorbidity burden [OR 1.43, 95% CI 1.15-1.78]), a primary indication of RMD (OR 1.37, 95% CI 1.27-1.48) and a positive anxiety or depression screen (OR 1.57, 95% CI 1.36-1.80). Modest differences in the proportion shielding were observed across nations. Conclusions Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
    Keywords covid19
    Language English
    Publishing date 2020-11-07
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2020.11.05.20226662
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study

    Mahil, Satveer K. / Dand, Nick / Mason, Kayleigh J. / Yiu, Zenas ZN. / Tsakok, Teresa / Meynell, Freya / Coker, Bola / McAteer, Helen / Moorhead, Lucy / Mackenzie, Teena / Rossi, Maria Teresa / Rivera, Raquel / Mahe, Emmanuel / Carugno, Andrea / Magnano, Michela / Rech, Giulia / Balogh, Esther A. / Feldman, Steven R. / De La Cruz, Claudia /
    Choon, Siew Eng / Naldi, Luigi / Lambert, Jo / Spuls, Phyllis / Jullien, Denis / Bachelez, Hervé / McMahon, Devon E. / Freeman, Esther E. / Gisondi, Paolo / Puig, Luis / Warren, Richard B. / Di Meglio, Paola / Langan, Sinéad M. / Capon, Francesca / Griffiths, Christopher EM. / Barker, Jonathan N. / Smith, Catherine H.

    Journal of Allergy and Clinical Immunology ; ISSN 0091-6749

    2020  

    Keywords Immunology ; Immunology and Allergy ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    DOI 10.1016/j.jaci.2020.10.007
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top